parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that ...

The One Medicine Platform replaces 20+ legacy platforms—unifying medicinal development processes & data sources into a ...

Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...

Privately-held Swedish firm Salipro Biotech AB, a specialist in the stabilization of challenging drug targets, today ...

Germany’s Boehringer Ingelheim has launched the One Medicine Platform, a new system designed to streamline drug development, ...

Cognizant (Nasdaq: CTSH) and Boehringer Ingelheim announced today the go-live of an end-to-end technology platform powered by ...

Salipro Biotech has signed a research and license agreement with Boehringer Ingelheim to accelerate the development of ...

The collaboration combines Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilise challenging drug targets from Boehringer Ingelheim’s drug discovery programs to enable ...

"With this new system, Boehringer Ingelheim is expected to resolve data challenges and latencies and speed up the go-to-market of its products. Thanks to the close collaboration across our teams ...

Boehringer Ingelheim is a biopharmaceutical company active in both ... Veeva Forward-looking Statements This release contains forward-looking statements regarding Veeva's products and services and the ...

Boehringer Ingelheim will conduct biophysical and structural studies ... We are not an agent for these third parties nor do we endorse or guarantee their products. We make no representation or ...

Boehringer Ingelheim and Veeva Systems have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They ...